Oct 19 2026 11:03 PM EST
Alignment Healthcare (NASDAQ: ALHC) saw its shares tumble roughly 43% from $13.03 on Sept 9 to $7.39 on Oct 9, a decline that coincided with a CMS star‑rating downgrade for its California HMO contract and a wave of analyst downgrades.
The downgrade cut the contract’s rating from 4.0 to 3.5 stars, eliminating eligibility for the 2028 quality bonus on roughly 75% of the company’s Medicare Advantage membership. In the same period, BofA Securities, UBS and several other houses reduced price targets by up to $16 and moved their recommendations to neutral or market‑perform.
Star‑Rating Downgrade Triggers Sell‑off
CMS released the 2027 star‑rating results in early October, dropping the California H3815 HMO contract to 3.5 stars. The contract accounts for more than three‑quarters of Alignment’s enrollment, and the lower rating removes the plan from the 2028 quality‑bonus pool. Management announced a lawsuit against CMS alleging procedural violations, but the legal action has not yet resolved the rating issue.
Q2 Results Show Strong Growth, Yet Margin Pressure Remains
For the quarter ended June 30, 2026, Alignment reported revenue of $1,335.6 million, up 31.6% YoY, and net income of $36.6 million versus $15.7 million a year earlier. Adjusted EBITDA reached $68.1 million (5.1% margin), a 48% increase YoY. Membership grew to 294,100, a 31% rise.
Guidance for Q3 2026 projects revenue of $1.30‑$1.32 billion and adjusted EBITDA of $20‑$30 million. Full‑year 2026 outlook was raised to revenue of $5.20‑$5.23 billion and adjusted EBITDA of $145‑$163 million, with the low end lifted by $7 million.
Macro and Regulatory Context
CMS’s final CY 2026 Medicare Advantage rate notice raised average payments by 5.06%, adding roughly $25 billion in federal funding. However, the V28 risk‑adjustment model entered its final phase in 2026, creating a short‑term headwind for plans with higher coding intensity, including Alignment’s high‑acuity C‑SNP/D‑SNP enrollments. Healthcare‑cost inflation ran at 1.5% YoY in September 2026, while Part D reforms under the Inflation Reduction Act added pricing pressure on high‑cost drugs.
Strategic Initiatives and Expansion
Alignment continues to expand its footprint, adding counties in North Carolina and California effective Jan 1, 2027, which together will cover more than 9.5 million Medicare‑eligible adults. The company is also investing in its AI‑enabled AVA Care platform, which it says identifies the 10% of members responsible for roughly 70% of hospitalizations and has begun improving the medical benefit ratio.
Insider Sales and Market Sentiment
Insider activity has added to the negative sentiment. CEO John E. Kao sold 27,400 shares on Sept 14, 2026 (≈ $356 k) and earlier disposed of 298,000 shares at prices ranging from $13.9 to $20 per share. EVP Joseph S. Konowiecki, President Dawn C. Maroney and other executives also sold shares, totaling roughly $6.6 million in the past six months.
Risks and Uncertainties
Key risks include the unresolved CMS star‑rating dispute, which could affect bonus payments and member retention; the V28 risk‑adjustment model that may compress margins on high‑cost members; and continued insider sell‑offs that may signal management’s confidence. Additionally, the modest 2027 payment increase of 0.09% offers limited upside to offset rising medical‑benefit costs. Investors will be watching the next earnings release on Oct 30 for evidence that the company can sustain its growth while navigating these regulatory and cost pressures.
&